October 2005 Issue
The Constant Gardener wont help the wilting image of our industry, but it may open dialogue on global standards for clinical trials.
Downsizing offers a quick fix, but has long-term costsand can even damage the bottom line. Whether youre on the giving or receiving end, the right approach is critical.
Tunable solvents, including supercritical fluids and ionic liquids, may not be in your stockroom yet but they offer significant environmental and manufacturing benefits.
Post-9/11 immigration policies threaten U.S. innovation.
As competitive pressures increase, drug makers are becoming increasingly concerned about their other pipeline: the human one. Is todays workforce up to the challenges now gripping the industry?
Any Time, Any Place, Any Product: A Roadmap for Successful International Pharmaceutical Plant Construction Projects
International relationships are preordained to be clumsy gestures based on imperfect knowledge. Rebecca West
As liability risks increase, drug manufacturers are assuming greater ownership of the cold chain for transporting valuable biologics. Stability testing, data logging and other technologies are helping to ensure product safety as the industry moves toward a whole new distribution model.
What works in the lab wont work in the plant: Success demands close control of parameters that depend on batch size.
The Canadian manufacturers Yield Check system has made a science out of managing totes and bins.